Tech Center 1600 • Art Units: 1624
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18252217 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | Final Rejection | Merck Sharp & Dohme LLC |
| 17607072 | MESOIONIC IMIDAZOLIUM COMPOUNDS AND DERIVATIVES FOR COMBATING ANIMAL PESTS | Final Rejection | BASF SE |
| 18502780 | NOVEL PRMT5 INHIBITORS | Non-Final OA | AMGEN INC. |
| 18555095 | NOVEL USE | Non-Final OA | DSM IP Assets B.V. |
| 18319895 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18319860 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18318914 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18572945 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17298599 | AMPA RECEPTOR ANTAGONISTS SPECIFIC FOR CALCIUM PERMEABLE AMPA RECEPTORS AND METHODS OF TREATMENT THEREWITH | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18570761 | METHOD FOR PRODUCING ISOXAZOLINECARBOXYLIC ACID DERIVATIVES | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18037217 | METHOD FOR PRODUCING KETONE DERIVATIVE | Non-Final OA | OSAKA UNIVERSITY |
| 18547618 | A QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THE PREPARATION THEREOF | Non-Final OA | ZYDUS LIFESCIENCES LIMITED |
| 18273678 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY | Final Rejection | Cornell University |
| 18646220 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | Non-Final OA | Denali Therapeutics Inc. |
| 18628635 | Substituted Macrocyclic Compounds and Related Methods of Treatment | Non-Final OA | Alkermes, Inc. |
| 17822863 | SULFATED PILLARARENES, METHODS OF MAKING SAME, AND USES THEREOF | Non-Final OA | University of Maryland, College Park |
| 18437558 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Final Rejection | Bial - R&D Investments, S.A. |
| 18294596 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | Non-Final OA | UNIVERSITY OF CAPE TOWN |
| 18290604 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | Non-Final OA | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED |
| 18581000 | NOVEL COMPOUNDS AND USES THEREOF | Non-Final OA | Royston Anthony GRAY |
| 18023164 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | Non-Final OA | Vicore Pharma AB |
| 18574248 | CRYSTALLINE POLYMORPHS OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR, AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | Crimson BioPharm Inc. |
| 18381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Non-Final OA | ZHEJIANG GENFLEET THERAPEUTICS CO.,LTD. |
| 18533681 | HOST DIRECTED DRUG COMBINATIONS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | SystaMedic Inc. |
| 18388554 | Pre And Post Natal Compositions Including Carotenoids | Non-Final OA | Maravilla, LLC |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Non-Final OA | MONTELINO THERAPEUTICS, INC. |
| 17292689 | USE OF AN ORGANOMETALLIC COMPOUND AS A DNA-DEMETHYLATING AGENT | Non-Final OA | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM |
| 18555250 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | Non-Final OA | ASIA VISION LIMITED |
| 18554353 | NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF | Non-Final OA | COSMAS THERAPEUTICS DEVELOPMENT INC. |
| 18554358 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | Final Rejection | UNIVERSITY OF OTTAWA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy